Ikena Oncology Operating Income 2021-2025 | IMA
Ikena Oncology operating income from 2021 to 2025. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Ikena Oncology Annual Operating Income
(Millions of US $) |
| 2024 |
$-59 |
| 2023 |
$-75 |
| 2022 |
$-71 |
| 2021 |
$-34 |
| 2020 |
$-45 |
Ikena Oncology Quarterly Operating Income
(Millions of US $) |
| 2025-03-31 |
$-11 |
| 2024-12-31 |
$-13 |
| 2024-09-30 |
$-12 |
| 2024-06-30 |
$-16 |
| 2024-03-31 |
$-18 |
| 2023-12-31 |
$-22 |
| 2023-09-30 |
$-20 |
| 2023-06-30 |
$-18 |
| 2023-03-31 |
$-16 |
| 2022-12-31 |
$-15 |
| 2022-09-30 |
$-18 |
| 2022-06-30 |
$-21 |
| 2022-03-31 |
$-17 |
| 2021-12-31 |
$3 |
| 2021-09-30 |
$-15 |
| 2021-06-30 |
$-13 |
| 2021-03-31 |
$-10 |
| 2020-12-31 |
$-34 |
| 2020-09-30 |
$-6 |
| 2020-06-30 |
$-5 |
| 2020-03-31 |
$-7 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.061B |
$0.009B |
|
Ikena Oncology Inc. is focused on developing cancer therapies targeting key signaling pathways which drive the formation and spread of cancer. The company's product candidates include IK-930, IK-175, IK-412 and IK-007, which are in clinical stage. Ikena Oncology Inc. is based in Boston, United States.
|
